Publicly Funded R&D In EU Should Come With Conditions, Says Report
Conditions should be attached to the public funding of biomedical R&D in response to escalating prices of drugs developed with public money, a new report says.
You may also be interested in...
Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.
The Netherlands will secure lower medicine prices by referencing Norway instead of Germany to set maximum prices.
Luxembourg’s new regulator will work to attract investment and improve public health as well as tackle the growing problem of drug shortages.